Targeted Oncology

Understanding the Role of Mutations in Staging of Low-Risk MDS

During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.
Yahoo Finance

Molecular International Prognostic Scoring System Developed for Myelodysplastic Syndromes

YARDVILLE, N.J., June 12, 2022 (GLOBE NEWSWIRE) -- Today, the MDS Foundation announced the development of a new prognostic scoring system, the IPSS-Molecular, that will significantly improve risk ...
The American Journal of Managed Care

Validating a New Scoring System in MDS for the Era of Next-Generation Sequencing

A well-regarded tool for predicting prognosis in myelodysplastic syndromes is updated to incorporate mutations and tested with real-world data. An abstract and poster presented at the 2023 American ...
Nature

The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)

The International Prognostic Scoring System (IPSS) was developed for adult MDS and includes weighted data on BM blast percentage, cytopenia, and cytogenetics, dividing patients into four prognostic ...
ascopubs.org

Validation of IPSS criteria in more than 1,600 MDS patients

Myelodysplastic syndromes (MDS) are a diverse group of clonal stem cell disorders characterized by bone marrow failure, dysmyelopoiesis and peripheral cytopenias and affecting predominantly an elderly ...
Business Wire

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

Subgroup analyses showed consistently higher transfusion independence (TI) response rates than placebo across different risk groups regardless of International Prognostic Scoring System (IPSS), ...
The American Journal of Managed Care

Study Finds Significant Survival Advantage for Patients With MDS Who Have HLA-Matched Donor for HCT

The abstract, presented at the 2020 American Society of Hematology Annual Meeting and Exposition, found favorable overall survival and leukemia-free survival for these patients. Compared with patients ...
ascopubs.org

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study Accurate determination of prognosis is critical for selection of ...
Medical Xpress

Team develops personalized prediction model for patients with MDS

At the American Society of Hematology (ASH) Annual Meeting, Cleveland Clinic medical hematologist and oncologist Aziz Nazha, M.D., will present results of a personalized prediction model that ...
Business Wire

Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from its IMerge Phase 3 clinical trial ...
Finanznachrichten

MDS Foundation, Inc. (963786): Molecular International Prognostic Scoring System Developed for Myelodysplastic Syndromes

YARDVILLE, N.J., June 12, 2022 (GLOBE NEWSWIRE) -- Today, the MDS Foundation announced the development of a new prognostic scoring system, the IPSS-Molecular, that will significantly improve risk ...